Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

[1]  H. Ehrlich,et al.  Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. , 2011, Vaccine.

[2]  T. Monath,et al.  An inactivated cell-culture vaccine against yellow fever. , 2011, New England Journal of Medicine.

[3]  C. Klade,et al.  Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. , 2010, Vaccine.

[4]  S. Halstead,et al.  Japanese encephalitis: new options for active immunization. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  B. Guy,et al.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. , 2010, Vaccine.

[6]  P. Pittman,et al.  Immune interference after sequential alphavirus vaccine vaccinations. , 2009, Vaccine.

[7]  D. Spelman,et al.  Ross River virus , 2022, CABI Compendium.

[8]  G. Gronvall.  Medical Aspects of Biological Warfare Edited by Zygmunt F. Dembek Falls Church, Virginia: Office of The Surgeon General, United States Army; Washington, DC: Borden Institute, Walter Reed Army Medical Center, 2007. 694 pp., Illustrated. $72.25 (hardcover) , 2009 .

[9]  A. Barrett,et al.  Vaccines for Biodefense and Emerging and Neglected Diseases , 2009 .

[10]  E. Gould,et al.  Safety concerns with regard to live attenuated flavivirus vaccines. , 2008, The Journal of infectious diseases.

[11]  H. Ehrlich,et al.  A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. , 2008, The New England journal of medicine.

[12]  B. Currie,et al.  Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia. , 2008, Vector borne and zoonotic diseases.

[13]  C. Klade,et al.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial , 2007, The Lancet.

[14]  F. Heinz,et al.  Field effectiveness of vaccination against tick-borne encephalitis. , 2007, Vaccine.

[15]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[16]  F. Dorner,et al.  The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. , 2007, Vaccine.

[17]  E. Gould,et al.  Live flavivirus vaccines: reasons for caution , 2004, The Lancet.

[18]  N. Verlander,et al.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial , 2003, The Lancet.

[19]  H. Ehrlich,et al.  Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. , 2003, Vaccine.

[20]  S. Ritchie,et al.  Ross River Virus Transmission, Infection, and Disease: a Cross-Disciplinary Review , 2001, Clinical Microbiology Reviews.

[21]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[22]  C. Tacket,et al.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. , 2000, The American journal of tropical medicine and hygiene.

[23]  C. Rossi,et al.  Immunologic interference from sequential administration of live attenuated alphavirus vaccines. , 1998, The Journal of infectious diseases.

[24]  C. Peters,et al.  Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. , 1996, Vaccine.

[25]  P. Jahrling,et al.  Venezuelan equine encephalitis‐specific immunoglobulin responses: Live attenuated TC‐83 versus inactivated C‐84 vaccine , 1992, Journal of medical virology.

[26]  A. I. McLeod,et al.  A Remark on Algorithm as 183. An Efficient and Portable Pseudo‐Random Number Generator , 1985 .

[27]  I. D. Hill,et al.  An Efficient and Portable Pseudo‐Random Number Generator , 1982 .

[28]  M. Ascher,et al.  Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). , 1979, The Journal of infectious diseases.

[29]  W. Thomas,et al.  Persistence in humans of antibody after immunization with four alphavirus vaccines. , 1979, Asian journal of infectious diseases.

[30]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[31]  A. Durbin,et al.  Dengue vaccine candidates in development. , 2010, Current topics in microbiology and immunology.

[32]  J. Aaskov.  Ross River Virus: Epidemic Polyarthritis , 2009 .

[33]  S. Yu,et al.  Development of a candidate vaccine against Ross River virus infection. , 1994, Vaccine.